- Home
- UFCS vs VIR Comparison
UFCS vs VIR Comparison
Compare UFCS & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UFCS | VIR |
|---|---|---|
| Founded | 1946 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 927.2M | 773.5M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | UFCS | VIR |
|---|---|---|
| Price | $36.93 | $6.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $33.00 | $25.73 |
| AVG Volume (30 Days) | 117.5K | ★ 1.8M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | ★ 118.04 | N/A |
| EPS | ★ 4.24 | N/A |
| Revenue | ★ $1,353,781,000.00 | $16,860,000.00 |
| Revenue This Year | $10.11 | N/A |
| Revenue Next Year | $3.33 | $48.05 |
| P/E Ratio | $8.68 | ★ N/A |
| Revenue Growth | ★ 12.12 | N/A |
| 52 Week Low | $24.11 | $4.16 |
| 52 Week High | $37.84 | $14.45 |
Technical Indicators
Market Signals| Indicator | UFCS | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 61.73 | 61.34 |
| Support Level | $33.53 | $6.49 |
| Resistance Level | $36.87 | $6.89 |
| Average True Range (ATR) | 0.97 | 0.44 |
| MACD | -0.13 | 0.05 |
| Stochastic Oscillator | 77.73 | 82.30 |
Price Performance
Historical ComparisonAbout UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.